DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RYDAPT
» See Plans and Pricing
All Clinical Trials for Rydapt
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia | Not yet recruiting | Novartis Pharmaceuticals | Phase 2 | 2017-10-01 | This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML. |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia | Not yet recruiting | University of Florida | Phase 2 | 2017-10-01 | This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML. |
| NCT03836209 | Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | Not yet recruiting | Astellas Pharma Inc | Phase 2 | 2019-07-01 | Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. |
| NCT03836209 | Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | Not yet recruiting | PrECOG, LLC. | Phase 2 | 2019-07-01 | Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. |
| NCT03900949 | Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Recruiting | Fred Hutchinson Cancer Research Center | Phase 1 | 2019-03-21 | This study is being done to evaluate the safety and tolerability of using the combination of gemtuzumab ozogamicin and midostaurin together with standard induction chemotherapy (cytarabine and daunorubicin) in the treatment of patients with newly diagnosed FLT-3 mutated acute myeloid leukemia (AML). The study will evaluate the benefit of adding gemtuzumab ozogamicin and midostaurin to standard induction chemotherapy efficacy, compared to standard induction for treating AML. |
| NCT03900949 | Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Recruiting | Oregon Health and Science University | Phase 1 | 2019-03-21 | This study is being done to evaluate the safety and tolerability of using the combination of gemtuzumab ozogamicin and midostaurin together with standard induction chemotherapy (cytarabine and daunorubicin) in the treatment of patients with newly diagnosed FLT-3 mutated acute myeloid leukemia (AML). The study will evaluate the benefit of adding gemtuzumab ozogamicin and midostaurin to standard induction chemotherapy efficacy, compared to standard induction for treating AML. |
| NCT03900949 | Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Recruiting | Pfizer | Phase 1 | 2019-03-21 | This study is being done to evaluate the safety and tolerability of using the combination of gemtuzumab ozogamicin and midostaurin together with standard induction chemotherapy (cytarabine and daunorubicin) in the treatment of patients with newly diagnosed FLT-3 mutated acute myeloid leukemia (AML). The study will evaluate the benefit of adding gemtuzumab ozogamicin and midostaurin to standard induction chemotherapy efficacy, compared to standard induction for treating AML. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Rydapt
Condition Name
Clinical Trial Locations for Rydapt
Trials by Country
Clinical Trial Progress for Rydapt
Clinical Trial Phase
Clinical Trial Sponsors for Rydapt
Sponsor Name
